TRVI

Trevi Therapeutics, Inc.

2.82 USD
+0.05 (+1.81%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Trevi Therapeutics, Inc. stock is down -0.7% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 5 May’s closed higher than April. 100% of analysts rate it a buy.

About Trevi Therapeutics, Inc.

Trevi Therapeutics is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.